High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma A multicentre study

I. Compter, K. Zaugg, R. M. A. Houben, J. T. A. Dings, G. Bosmans, C. Buescher, M. M. H. M. E. Anten, B. G. Baumert*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Purpose. The goal of the present study was to analyze long-term results of fractionated stereotactic radiotherapy (SRT) in patients with a meningioma. Methods and materials. A total of 72 patients treated between 1996 and 2008 in MAASTRO clinic (n = 45) and University Hospital Zurich (n = 27) were included. SRT was given as primary treatment (n = 46), postoperatively (n = 19) or at recurrence (n = 7); 49 tumours (68%) were located in the skull base. Median total dose was 54 Gy. Results. Median follow-up was 4.13 years (range 0.66-11 years). The 3- and 5-year overall survival were 92 and 79% for grade 0 and I meningioma. Progression-free survival for grade 0 and I was 95% at 3 and 5 years, and 40% for grade II and III at 3 years. In 98.4% of patients, clinical symptoms were stable or improved. The majority of symptoms improved within 24 months after SRT. Local control is significantly better if patients are irradiated immediately after diagnosis compared to a watchful waiting policy (p = 0.017). Grade IV toxicity was low (4.2%, n = 3) Conclusion. SRT is an effective treatment with high local and clinical control. Early SRT resulted in better outcome than late treatment at progression.
Original languageEnglish
Pages (from-to)887-893
JournalStrahlentherapie Und onkologie
Issue number10
Publication statusPublished - Oct 2012


  • Meningioma
  • Skull base
  • Stereotactic radiotherapy
  • Toxicity
  • Long-term follow-up

Cite this